Student Research Committee, Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
UKM Medical Molecular Biology Institute, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
Biomed Pharmacother. 2022 Apr;148:112743. doi: 10.1016/j.biopha.2022.112743. Epub 2022 Feb 25.
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel therapeutics. The CRISPR-Cas9 system has been recently proposed as a potential therapeutic tool for the treatment of viral diseases. Here, we review the research progress in the use of CRISPR-Cas technology for treating viral infections, as well as the strategies for improving the delivery of this gene-editing tool in vivo. Key challenges that hinder the widespread clinical application of CRISPR-Cas9 technology are also discussed, and several possible directions for future research are proposed.
病毒感染是全球发病率的常见原因。2019 年冠状病毒病（COVID-19）的出现导致人们更加关注病毒感染和寻找新的治疗方法。CRISPR-Cas9 系统最近被提议作为治疗病毒疾病的潜在治疗工具。在这里，我们回顾了使用 CRISPR-Cas 技术治疗病毒感染的研究进展，以及改善该基因编辑工具体内递送的策略。还讨论了阻碍 CRISPR-Cas9 技术广泛临床应用的关键挑战，并提出了未来研究的几个可能方向。
